PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2018 | nr 1 | 20--33
Tytuł artykułu

Treatment Options in Chronic Lymphocytic Leukemia (CLL) - a Polish Perspective

Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia among the elderly people in Western societies. CLL is genetically and molecularly heterogeneous disease that translates into clinical outcomes. Currently, the most unfavorable prognosis is associated with the presence of deletion of the short arm of chromosome 17 (del17p) and/or mutation of the TP53 gene (mTP53) that requires an individualized therapeutic approach. Allogenic hematopoietic stem cells transplantation (allo-HSCT) is still the only potentially curative treatment option in patients with CLL. Nevertheless, it is associated with high toxicity and treatment-related mortality. Therefore, it can be used only in selected patients, mostly young and fit without significant comorbidities. Moreover, allo-HSCT should be performed in patients who achieve disease remission. Recent advances in molecular biology have led to the better understanding of CLL pathophysiology and development of new targeted therapies. Recently developed and approved drugs such as new anti-CD20 monoclonal antibodies (obinutuzumab, ofatumumab), B-cell receptor inhibitors (BCRi) (ibrutinib, idelalisib) and B-cell lymphoma 2 (BCL-2) protein inhibitor (venetoclax) provide better clinical outcomes in CLL patients than previously used standard chemotherapy regimens. Most of those new drugs have been included in treatment algorithms described in Polish, European and global clinical practice guidelines. However, not all of them are available for Polish patients due to the lack of reimbursement, leaving them in the clinical unmet need state. This review summarizes recent advances in CLL treatment, focusing on the Polish perspective. (original abstract)
Słowa kluczowe
Rocznik
Numer
Strony
20--33
Opis fizyczny
Twórcy
  • HTA Consulting, Kraków, Poland
  • HTA Consulting, Kraków, Poland
  • HTA Consulting, Kraków, Poland
autor
  • Medical University of Lublin
Bibliografia
  • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. (2018) Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Bloodblood-2017-09-806398.
  • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446-5456.
  • Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, al. R et. (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375-2390.
  • Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343(26):1910-1916.
  • Puiggros A, Blanco G, Espinet B, Puiggros A, Blanco G, Espinet B. (2014) Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go, genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. BioMed Res. Int. 2014:435983.
  • Hallek M, Shanafelt TD, Eichhorst B. (2018) Chronic lymphocytic leukaemia. The Lancet 391(10129):1524-1537.
  • Jamroziak K, Puła B, Walewski J. (2017) Current treatment of chronic lymphocytic leukemia. Curr. Treat. Options Oncol. 18(1):5.
  • Scarfò L, Ferreri AJM, Ghia P. (2016) Chronic lymphocytic leukaemia. Crit. Rev. Oncol. Hematol. 104:169-182.
  • Warzocha K. (2013) Wytyczne PTOK. Przewlekła białaczka limfocytowa. PTOK Available from: http://onkologia.zalecenia.med.pl/pdf/zalecenia_PTOK_2013_tom2_ksiazka_2_NUC_przewlekla_bial_limfocytowa.pdf.
  • Gajewski P. Interna Szczeklika. Podręcznik chorób wewnętrznych. Kraków 2016.
  • Gajewska A. (2009) Rola receptora BCR (B-cell receptor) w rozwoju przewlekłej białaczki limfocytowej z komórek B (PBL-B). Acta Haematol. Pol. 40(1):35-43.
  • (2018) NCCN guidelines for patients. Chronic lymphocytic leukemia. Available from: https://www.nccn.org/patients/guidelines/cll/ (4.6.2018).
  • SEER stat fact sheets: chronic lymphocytic leukemia (CLL). Available from: http://seer.cancer.gov/statfacts/html/clyl.html (15.11.2016).
  • Hodgson K, Ferrer G, Pereira A, Moreno C, Montserrat E. (2011) Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br. J. Haematol.154(1):14-22.
  • Białaczki | KRN. Available from: http://onkologia.org.pl/bialaczki/ (7.9.2016).
  • Watson L, Wyld P, Catovsky D. (2008) Disease burden of chronic lymphocytic leukaemia within the European Union. Eur. J. Haematol. 81(4):253-258.
  • Orphanet: B cell chronic lymphocytic leukemia. Available from: http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=10899&Disease_Disease_Search_diseaseGroup=chronic-lymphocytic-leukemia&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group of diseases=B-cell-chronic-lymphocytic-leukemia&title=B-cell-chronic-lymphocytic-leukemia&search=Disease_Search_Simple (18.11.2016).
  • Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. (2014) Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol.15(9):931-942.
  • Didkowska J, Wojciechowska U, Gierczyński J, Warzocha K, Lech-Maranda E. (2016) Zachorowalność i umieralność u chorych na przewlekłą białaczkę limfocytową w Polsce w latach 1999-2013. Hematologia 7(2):108-116.
  • Rai KR, Stilgenbauer S. (2018) Staging and prognosis of chronic lymphocytic leukemia. UpToDate.
  • Foà R, Del Giudice I, Guarini A, Rossi D, Gaidano G. (2013) Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 98(5):675-685.
  • Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, al. A et. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood114(5):957-964.
  • Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. (2015) Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood125(13):2062-2067.
  • Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. (2015) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 1(1):80-87.
  • Sharma S, Galanina N, Guo A, Lee J, Kadri S, Slambrouck CV, al. B et. (2016) Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget 7(42):68833-68841.
  • Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24):1750-1757.
  • Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, et al. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet Lond. Engl. 370(9583):230-239.
  • Eichhorst BF. (2005) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood107(3):885-891.
  • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet Lond. Engl.376(9747):1164-1174.
  • Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, et al. (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 17(7):928-942.
  • Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. (2015) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 26 Suppl 5:v78-84.
  • Eichhorst B, Robak T, Montserrat E, ESMO. (2016) ESMO eUpdate - chronic lymphocytic leukaemia treatment recommendations. Available from: http://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Lymphocytic-Leukaemia/eUpdate-Treatment-Recommendations.
  • Eichhorst B, Robak T, Montserrat P. (2017) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. - eUpdate June 2017. Available from: http://www.esmo.org/Guidelines/Haematological-Malignancies/Chronic-Lymphocytic-Leukaemia/eUpdate-Treatment-Recommendations.
  • Robak T, Hus I, Giannopoulos K. (2016) Wytyczne PTHiT/PALG-CLL. Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r - Raport Grupy Roboczej PTHiT i PALG-CLL. Acta Haematol. Pol. 47:169-183.
  • Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208-215.
  • Robak T, Hus I, Błoński J, Giannopoulos K, Jamroziak K, Roliński J, et al. (2014) Wytyczne PTHiT/PALG-CLL Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. - raport Grupy Roboczej PTHiT oraz PALG - CLL. Acta Haematol. Pol. 45(3):221-239.
  • Hallek M. (2015) Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 90(5):446-460.
  • SmPC Arzerra (ofatumumab). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001131/WC500093091.pdf (5.6.2018).
  • SmPC Gazyvaro (obinutuzumab). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002799/WC500171594.pdf.
  • Rai KR, Stilgenbauer S. (2018) Treatment for relasped/refractory chronic lymphocytic leukemia. UpToDate.
  • Rai KR, Stilgenbauer S. (2018) Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia. UpToDate.
  • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, Serna J de la, Dilhuydy M-S, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer K-A, Stilgenbauer S, i in. (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370(12):1101-1110.
  • Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, al. N et. (2017) NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. J. Natl. Compr. Canc. Netw. 15(3):293-311.
  • Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. (2015) Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. The Lancet 385(9980):1873-1883.
  • Obwieszczenie Ministra z dnia 26 lutego 2018 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Available from: http://www.mz.gov.pl/wp-content/uploads/2018/02/solr-zalacznik-do-obwieszczenia-1.pdf.
  • SmPC Imbruvica (ibrutinib). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf.
  • Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, i in. (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373(25):2425-2437.
  • Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371(3):213-223.
  • O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. (2016) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol.17(10):1409-1418.
  • SmPC Zydelig (idelalisib). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003843/WC500175377.pdf.
  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med.370(11):997-1007.
  • (2016) EMA recommends new safety measures for Zydelig. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/03/WC500203474.pdf (27.4.2018).
  • SmPC Venclyxto (venetoclax). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004106/WC500218800.pdf.
  • Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 17(6):768-778.
  • Seymour J, Davids MS, Roberts AW. Safety profile of venetoclax monotherapy in patients with chronic lymphocytic leukemia (poster 4395). ASH; 6 grudnia 2016; San Diego, Kalifornia, USA. .
  • European Medicines Agency. (2016) CHMP assessment report. Venclyxto.
  • Stilgenbauer S, Chyla B, Eichhorst B. Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. P420. XVII International Workshop on Chronic Lymphocytic Leukemia; maj 2017; New York, USA. .
  • Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. (2017) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol.
  • Jones JA. (2016) Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. J. Clin. Oncol. 34:abstr 7519.
  • Jones JA. Venetoclax is active in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. 2016 ASCO Annual Meeting; 2016Board
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.ekon-element-000171542272

Zgłoszenie zostało wysłane

Zgłoszenie zostało wysłane

Musisz być zalogowany aby pisać komentarze.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.